Investigation of the usefulness of a screening test for pancreatic cancer based on highly sensitive detection of gene mutations in duodenal juice collected using synthetic human secretin and a specially-made catheter following conventional gastrointestinal endoscopy in high-risk individuals

Yachida Shinichi0 个研究点目标入组 120 人开始时间: 2021年1月22日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patient-provided informed consent and over 20 years old
•2) Patients in high-risk groups for pancreatic cancer (Onomichi City Cohort, Matsue City Cohort, Kokugan Cohort, Osaka National Cancer Center Cohort, Wakayama Medical University Cohort, Aichi Cancer Center Cohort) on whom EUS,EUS-FNA, or ERCP will be performed
•3) Persons who have given their written consent to participate in this research

•1) Patients with hypersensitivity to secretin or other ingredients (excipients: cysteine hydrochloride and mannitol)
•2) Patients in remission from acute pancreatitis or acute exacerbations of chronic pancreatitis within 2 weeks of the start of administration of the study drug
•3) Patients who don't discontinue anticholinergic drugs at least 5 half-lives prior to the start of administration of the study drug
•4) Pregnant or lactating women
•5) Patients who received other research drugs or investigational drugs within 3 months of the start of administration of the study drug
•6) Patients who are hard to observe a duodenal papilla with an endoscope
•7) Patients whom the doctor in charge judges inappropriate

发起方

Yachida Shinichi